Balyasny Asset Management L.P. Makes New $3.98 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Balyasny Asset Management L.P. acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 529,653 shares of the biotechnology company's stock, valued at approximately $3,983,000. Balyasny Asset Management L.P. owned about 0.26% of BioCryst Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Venturi Wealth Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $46,000. R Squared Ltd bought a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $48,000. KBC Group NV raised its stake in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after acquiring an additional 4,537 shares during the period. Raymond James Financial Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $80,000. Finally, Syon Capital LLC bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $99,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX traded down $0.21 on Wednesday, hitting $9.85. 8,983,531 shares of the stock were exchanged, compared to its average volume of 3,035,928. The stock has a fifty day moving average price of $7.96 and a two-hundred day moving average price of $7.92. The firm has a market capitalization of $2.06 billion, a P/E ratio of -16.15 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a 52-week low of $5.90 and a 52-week high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. The firm's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period last year, the firm earned $0.28 earnings per share. Sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on BCRX shares. Needham & Company LLC lifted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price objective on the stock. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $16.56.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.